Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial

Overview of attention for article published in Frontiers in immunology, October 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (61st percentile)
Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

twitter: 6 X users

Readers on

mendeley: 22 Mendeley

Summary X

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 41,187 followers.

Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial https://t.co/YPntIlni7J https://t.co/oioxU7JTw6

01 Nov 2023

Reply Repost Favourite

RT @MalariaPapers: Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised…

01 Nov 2023

Reply Repost Favourite

Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial https://t.co/Vta4LgWTyR

01 Nov 2023

Reply Repost Favourite

RT @bougouma_edith: Je vs invite à lire ntre intéressant article paru le 16/10/22 au lien ci-dessous: Safety and immunogenicity of BK-SE36/…

17 Oct 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.